 For those randomized to group B NOAC group, patients will be treated using a registered NOAC rivaroxaban, apixaban or dabigatran, but preferentionally apixaban at the dose recommended by the manufacturer in a case of apixaban 5 mg or 2.5 mg twice daily and adjusted relative to comorbidities body weight, age, and renal function. 